Fancy reducing 39%BF in four weeks?

[liquid_101]

saw this this morning when checking emails - not exactly a science abstract - but interesting none the less. this been used before?

http://lifestyle.aol.co.uk/2011/11/10/new-jab-gets-rid-of-39-of-body-fat-in-a-month/?ncid=webmail5

The battle against obesity has seen the rise of boot camps, extreme diets and medical procedures such as gastric band surgery.

A new way of fast weight loss could be on the way if the results of a new trial to test fat-busting injections prove safe on human volunteers.

In tests the drug Adipotide, when given on a daily basis, reduced body fat by 39% and stomach fat by 27% in four weeks.

Researchers allowed monkeys to gain weight by eating too much and not exercising, then injected them with the drug.

The monkeys lost 11% of their weight in a month and the team said the results were so promising they were keen to start testing the drug on obese people.

Although the team from the MD Anderson Cancer Centre at the University of Texas said some of the monkeys had kidney problems from the jab, they thought this issue could be resolved.

The injectable targets blood vessels in the body which give fat a blood supply and makes them die, while also reducing appetite.

Researcher Dr Wadih Arap said: "Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use. Obese cancer patients do worse in surgery, with radiation or chemotherapy – worse by any measure."

[Kracka]

four.

[Diab0lic]

Did a bit of digging and can't find much actual data except what you said:

"Ten monkeys were treated and five were the control group. At the end of the study, treated monkeys lost an average of 38.7 percent of their total body fat, compared to 14.8 percent for the control animals.

Treated monkeys also lost 27 percent of their abdominal fat.

Monkeys remained bright and alert throughout the study. The chief side effects were increased urine output and slight dehydration, both symptoms of mild kidney failure. But these were reversible and varied by dose."

As far as development data goes:

"Ablaris Therapeutics (a subsidiary of Arrowhead Research Corporation) is developing technology licensed from the University of Texas M. D. Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions. Development is at the preclinical stage in the US.

The technology leads to compounds which are designed to specifically kill blood vessels feeding adipose tissue. These compounds are administered via subcutaneous injection and early studies have shown that they produce appetite suppression but do so by acting at adipose tissue rather than by acting directly on the brain.

As part of the exclusive worldwide license agreement between the University of Texas M. D. Anderson Cancer Center and Ablaris Therapeutics (Arrowhead Research Corporation), Ablaris is not responsible for any direct costs associated with preparing for, or running, an initial phase I clinical trial.

Ablaris is planning a phase I trial of its obesity therapy (administered as a subcutaneous injection) in healthy volunteers in the US. FDA-required preclinical toxicity studies are nearly complete and a drug candidate is expected to enter clinical development in 2011.

Preclinical data have been generated in rodents and three different species of non-human primates. Results showed that administration of the compounds led to the destruction and absorption of adipose tissue in study animals. Weight loss seen in the animals was due to a combination of destruction of fat and a decrease in appetite and resulting food intake."

They have not disclosed the mechanism of action yet, but from reading this:

"The drug works by seeking out and sticking to proteins on the surface of blood vessels that feed white fat cells -- the kind that gathers under the skin and around the middle. Once attached, the drug releases a synthetic molecule that triggers a natural process of cell death that kills the fat cells"

it sounds like it could be a monoclonal antibody delivery system, but who knows what the actual active compound is? It's obviously has stemmed from oncology research (developed by M.D Anderson cancer centre and it's a drug that targets the vascular supply like many antitumour drugs) but it could be one of a number of drug classes.

Intredasting...

[liquid_101]

four.

am utterly useless until my first morning coffee